Why the study?
Does in vitro heparin exposure affect platelet count and aggregation in patients previously exposed to heparin compared to controls?
Does in vitro heparin exposure affect platelet count and aggregation in patients previously exposed to heparin compared to controls?
Prior exposure to heparin is associated with increased in vitro platelet aggregation and lower platelet counts when blood is re-exposed to heparin, suggesting the development of a proaggregator or antibody.
Answers are grounded in this paper and cite their sources.
Prior heparin exposure was associated with in vitro platelet changes; hypothesis-generating for proaggregatory antibodies and should not yet alter practice.
The in vitro effect of heparin on platelet aggregation was studied in three groups: in 26 subjects recently treated with heparin, in 18 subjects on maintenance hemodialysis, and in 20 normal controls. With the aid of Technicon H6000, platelet counts and platelet aggregations were compared in whole blood samples collected in ethylenediaminetetraacetic acid (EDTA) and in heparinized tubes. Although there was no significant difference between platelet count of heparinized and EDTA blood in the control group, the dialysis group and the group recently treated with heparin showed significantly lower platelet counts and more platelet aggregation in heparinized tubes than in EDTA tubes. We speculate that the majority of subjects exposed to heparin develop an antibody or a proaggregator which can aggregate or agglutinate platelets in the presence of heparin and causes destruction of platelets; but only in a small percentage of subjects receiving heparin is this reaction severe enough to cause thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Shojania et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: